The aim of this study was to determine whether a selective increase in the level of insulin in the blood perfusing the brain is a determinant of the counterregulatory response to hypoglycemia. Experiments were carried out on 15 conscious 18-h-fasted dogs. Insulin was infused (2 mU/kg per min) in separate, randomized studies into a peripheral vein (n = 7) or both carotid and vertebral arteries (n = 8). This resulted in equivalent systemic insulinemia (84±6 vs. 86±6 jU/ml) but differing insulin levels in the head (84±6 vs.
cludes direct regulation of metabolism is poorly understood and often debated. One reason for this controversy is the lack of evidence from studies on conscious subjects that circulating insulin, the major regulator of carbohydrate, fat, and protein metabolism, exerts direct effects upon the brain. Previous in vitro studies have been divided on whether insulin can influence cerebral glucose utilization (1) (2) (3) (4) (5) (6) . This has tended to reinforce the classical belief that the brain is an insulin-insensitive organ. However, this view has been widely challenged. Insulin receptors have been demonstrated in widespread regions of the brain (7, 8) , thereby providing a mechanism for direct insulin action. Furthermore high affinity insulin receptors have also been reported in brain microvessels which provide a pathway for blood borne insulin to cross the blood-brain barrier and activate insulin receptors within the brain (9) . Insulin when injected into the carotid artery of anesthetized dogs (10) and rats, in the absence of hypoglycemia, produced cardiovascular (10) , and systemic metabolic changes (11) . In addition, microinjection of insulin into specific regions of the rat brain (12-13) (hypothalamus and preoptic area) has also resulted in systemic changes in carbohydrate and lipid metabolism. Nevertheless, despite the above reports and data indicating that certain forms of obesity may be due to defective brain insulin responsiveness (8, 14) , convincing data are lacking from conscious subjects which demonstrate direct physiologic effects of blood-borne insulin on the brain.
We have recently demonstrated in conscious dogs (15) and normal human (16) that increased insulin levels can amplify the ANS (epinephrine and norepinephrine) response to a given hypoglycemia. Kerr et al. (17) and Davis et al. (18) have also demonstrated amplification of the sympathetic nervous system response to hypoglycemia by insulin in insulin-dependent diabetic human. Other studies, in which microneurography was used, have demonstrated that insulin can increase sympathetic nerve activity even under euglycemic conditions (19, 20) . However, it has been argued that the increase in sympathetic nerve activity during hyperinsulinemic euglycemia may be due to baroreceptor responses to insulin induced vasodilation rather than direct insulin effects upon the central nervous system (19) . Thus, the site of insulin sensing could not be identified from the above studies. A hypothesis which would bring together the above data would be one which proposes that activation of the ANS results from the brain directly responding to the circulating insulin level. This hypothesis, previously suggested by Szabo and Szabo (11) , although plausible has not been definitively tested in the conscious animal. The aim of the present study therefore was to determine in conscious normal dogs whether a selective, physiologic increment in the insulin level of the blood perfusing the brain could amplify the neuroendocrine response to hypoglycemia.
Methods
Animals. Experiments were carried out on 15 normal, conscious 18-hfasted dogs of either sex (weight 20.3-24.9 kg, mean 22±0.4 kg), which were fed a meat and chow diet (31% protein, 52% carbohydrate, 11% fat, 6% fiber; Kal Kan meat and Wayne dog chow) once daily for 3-4 wk before each study. The dogs were housed in a surgical facility that met the guidelines of the American Association for the Accreditation of Laboratory Animal Care, and the protocols were approved by the Vanderbilt University Medical Center Animal Care Committee.
Surgical procedures. 16 d before each experiment, catheters were inserted into a hepatic vein, the portal vein and a femoral artery under general anesthesia as previously described (21). One week later each animal underwent a second operation (again under general anesthesia) during which silastic catheters were placed into both carotid and vertebral arteries and a jugular vein as previously described (22) . The catheters were filled with heparinized saline, knotted, and placed into subcutaneous pockets. Due to problems in availability Doppler flow probes (Instrumentation Development Laboratories, Baylor College of Medicine, Houston, Texas) were placed around the portal vein and the hepatic artery in only eight dogs. On the day of the experiment the catheters and doppler leads were exteriorized from their subcutaneous pockets (under local anesthesia, 2% lidocaine; Astra, Worcester, MA). The contents of each catheter were aspirated, and heparinized saline ( 1 U/ ml) was infused into them at a slow rate (0.1 ml/min). Blood was subsequently sampled from the arterial, portal vein, and hepatic vein catheters. Insulin was administered via both carotid and vertebral arteries or a percutaneous catheter inserted into a cephalic vein. As insulin is neither extracted, sequestered, or synthesized by the brain to any appreciable amounts any insulin infused directly into the carotid and vertebral arteries will traverse the head and overflow into the systemic circulation. Consequently, systemic insulin levels obtained during a constant infusion into the carotid and vertebral arteries would be expected to be equivalent to systemic levels obtained during an identical peripheral rate of insulin administration. When insulin was administered peripherally saline was administered at an equivalent rate into both carotid and both vertebral arteries. In this way, each dog received equivalent infusions of fluid into the head during each experiment. Radioactive tracers, indocyanine green, and glucose were administered via a catheter in the other cephalic vein.
Experimental design. Each experiment consisted of a tracer equilibration (-120--40 min), a control (-40-0 min) and an experimental period (0-180 min). A priming dose of purified [3-3H] glucose (50 ACi) was given at -120 min, followed by a continuous infusion of [3-3H] (24) .
Plasma glucose concentrations were measured in quadruplicate using the glucose oxidase method in a Beckman Glucose Analyzer II (Fullerton, CA). Whole blood alanine lactate, glycerol, and 3-hydroxybutyrate concentrations were determined in samples deproteinized with 4% (wt/ vol) perchloric acid (PCA; 1 ml blood + 3 ml PCA) with the method developed by Lloyd et al. (25) for the Technicon Autoanalyzer. Blood acetoacetate levels were determined on the above supernatant with a spectrophotometric assay (26) . Plasma non-esterified fatty acid (NEFA) concentrations were determined according to the method of Ho (27) . Immunoreactive glucagon was measured according to the method of Aguilar-Parada et al. (28) with an interassay C.V. of 15%. Immunoreactive insulin was measured as described previously (29) with an interassay C.V. of 11%. Catecholamines were determined by HPLC (30) with an interassay C.V. of 17% for epinephrine and 14% for norepinephrine. Two modifications in the procedure for catecholamine determination were made. (a) A five-rather than one-point standard calibration curve was used; (b) aliquots of the initial and final samples of plasma were spiked with known amounts of epinephrine and norepinephrine so that accurate identification of the respective catecholamine peaks could be made. Cortisol was assayed using the Clinical Assays Gamma Coat RIA Kit with an interassay C.V. of 6%. Pancreatic polypeptide was measured using the method of Hagopian et al. (31) and hepatic vein concentrations, and Q is the flow (blood or plasma as required) to the liver as determined by the use of Indocyanine green. All hepatic balances are depicted as positive values, but are labeled appropriately as either output or uptake. The proportion of the hepatic blood supply provided by the hepatic artery was assumed to be 20% based on mean data obtained from doppler flow probes placed on the hepatic artery and portal vein (n = 8 dogs). The increase in hepatic blood flow observed during hypoglycemia in the present experiments was due to proportional changes in both portal vein and hepatic artery flows which is consistent with previous findings (32) .
The rates of tracer determined glucose appearance (Ra) and utilization (Rd) were calculated according to the methods of Wall et al. (33) as simplified by Debodo et al. (34) . R. is comprised of both endogenous (hepatic) glucose production and the exogenous glucose infusion. By subtracting the total amount of exogenous glucose infused from total Ra, hepatic glucose production can be derived. It is now recognized that this model is not fully quantitative, as underestimates of total R. and Rd can be obtained. By using a highly purified tracer and making measurements under steady state conditions (i.e., constant specific activity) these problems can be minimized. The hepatic ['4C I glucose production rate, a measure of the overall gluconeogenic rate, was determined using the tracer technique as described elsewhere (35) .
The efficiency of the hepatic conversion of alanine to glucose, which reflects the intrahepatic gluconeogenic process, was calculated by dividing the ['4C] glucose production by the rate of net [14C] alanine and [ 4C] lactate uptake by the liver. This parameter is a minimal estimate of the actual efficiency since the "4C-specific activity in the gluconeogenic precursor pool within the hepatocyte is diluted at the oxalo acetate level. The overall gluconeogenic rate (pimol/kg per min) can be estimated in two ways. One can assume that all of the gluconeogenic precursors extracted by the liver are completely converted to glucose and thereby calculate a maximal estimate of this process. To do this in the present study, the net uptake of pyruvate was assumed to be 1/10 that of lactate (36) and the net uptake of gluconeogenic amino acids other than alanine was assumed to be equivalent to that of alanine (37) . Alternatively, the net hepatic uptake of all gluconeogenic precursors can be multiplied by the calculated gluconeogenic efficiency to give a minimal estimate of the process. The contribution of gluconeogenesis to overall glucose production can then be calculated by dividing either of the above by 2 to account for the incorporation of the C-3 precursors into the C-6 glucose molecule and then dividing this quotient by the net hepatic glucose balance (ttmol/kg per min) and multiplying by 100. In this way quantitative brackets can be given to the gluconeogenic process.
Statistical analysis. Data are expressed as means±SE unless otherwise stated, and analyzed using standard, parametric two way analysis of variance with a repeated measures design. This was coupled with the paired students t test to delineate at which time statistical significance was reached. A value of P < 0.05 indicated significant difference.
Results
Insulin, glucose, and counterregulatory hormone levels. Insulin infusions resulted in equivalent steady state levels by 60 min in head and peripheral administration studies. During the final 120 min of each experiment, systemic arterial insulin levels were stable (CV during head infusion = 3.6%, CV during peripheral infusions = 3.0%) at 84±6 and 86±6 ,U/ml for head and peripheral infusions respectively. Basal insulin levels were similar in each group (12±2 uU/ml). As insulin is neither extracted nor sequestered by the brain, jugular vein insulin levels can serve as an accurate measure of the cerebral insulin concentration. In the present study, the jugular vein insulin level was measured in three animals and found to be 195±5 XU/ml during carotid and vertebral insulin infusion, a value close to the predicted estimate (22) given the infusion rate used. Glucose was infused in the peripheral insulin infusion group so as to equate the rate of fall (1.07 mg/min) and the plateau glucose level (58±2 vs. 56±2 mg/dl) in the head and peripheral infusion groups respectively (Fig. 1 ). The glucose infusion rate was increased slowly to 2.0±0.3 mg/kg per min by 90 min and then was maintained at this rate for the remainder of the 180 min experimental period. The stability of the plasma glucose level during the last 60 min of each protocol was demonstrated by a C.V. of 1.1±0.1%.
In response to hypoglycemia the plasma levels of the counterregulatory hormones (epinephrine, norepinephrine, cortisol, glucagon) and pancreatic polypeptide all increased compared with baseline (P < 0.001). Despite similar hypoglycemia, epinephrine ( Fig. 2 ) increased significantly more during head (basal 240±51 to 2394±312 pg/ml) than peripheral (basal 180±45 to 792±198, P < 0.001) insulin infusion. Similarly plasma norepinephrine (303±50 to 778±93 vs. 258±48 to 404±33 pg/ml, P < 0.01) and cortisol (2.7±0.6 to 9.8±1.6 vs.
1.5±0.3 to 6.3±1.8 jzg/dl, P < 0.05) were also significantly increased during the head compared to peripheral insulin infusions. Pancreatic polypeptide, an indirect marker of parasympathetic activity, also increased to a greater extent during the head insulin infusion (219±53 to 1061±64 vs. 251±64 to 722±273 pg/ml, P < 0.05). Unlike the preceding counterregulatory hormones there was no significant difference in the plasma glucagon responses in the two protocols (Fig. 3) .
Glucoseflux. Glucose specific activity (dpm/mg) was in a similar steady state during the control period of the head and peripheral insulin infusions (C.V. of glucose specific activity = 1.5% head and 1.7% peripheral). Table I demonstrates the time course of the change in glucose specific activity. By the final 60 min of each insulin infusion period, an isotopic steady state existed with a C.V. of 0.7 and 2.9% in the head and peripheral groups respectively. Hepatic glucose production (Fig. 4) was initially similar (2.6±0.4 mg/kg per min) in both groups, remained unchanged (2.6±0.5 mg/kg per min) during peripheral infusion but increased during head infusion (4.3±0.4 mg/kg per min, P < 0.001). This response was confirmed by the A-V difference data (Table II) .
Glucose utilization increased as the plasma glucose fell during the first 45 min of hormone infusion in both protocols. When the glucose level had stabilized the rates of glucose utilization (4.3±0.3 vs. 4.6±0.5 mg/kg per min) and clearance (7.6+0.6 vs. 7.8±0.7 ml/kg per min) were similar during both head and peripheral insulin infusions.
Gluconeogenic precursor metabolism. Hepatic blood flow was similar at the start of the head and peripheral insulin infusions (28±2 vs. 36±6 ml/kg per min, respectively). It remained at basal levels during peripheral infusion but increased significantly to 44±4 ml/kg/min (P < 0.001) during head insulin infusion. Arterial blood lactate levels were increased ( Arterial blood alanine levels fell similarly during head (401±33 to 234±29 ,AM) and peripheral insulin infusion (354±51 to 176±23 AM). Due to increased hepatic blood flow and therefore a greater delivered load, net hepatic uptake of alanine increased significantly during head infusion (2.8±0.3 to 5.9±0.9 jsmol/kg per min, P < 0.001) but remained at control rates during peripheral insulin infusion (2.9±0.4 to 2.8±0.4 ,Amol/kg per min). Fractional extraction of alanine, however, increased similarly during head (40±5 to 67±4%) and peripheral insulin infusion (28±4 to 54±4%).
Gluconeogenic parameters. The efficiency with which the liver converted alanine and lactate to glucose (Table V) increased similarly during head (25±9 to 53±9%) and peripheral insulin infusion (20±8 to 44±8%). During the last hour of head insulin infusion, gluconeogenesis contributed minimal and maximal estimates of 2.5 and 4.3 mg/kg per min of total hepatic glucose production. During the last hour of peripheral insulin infusion these estimates were 0.8 and 1.8 mg/kg per min, respectively. Thus with the head enriched with insulin gluconeo- genesis contributed 65 to 100% of glucose production as opposed to 32 to 72% when the brain was not insulin enriched.
Ketone body and non-esterifiedfatty acid (NEFA) metabolism. Plasma NEFA levels (Table Im) increased by a significantly greater amount (P < 0.05) during head (774±124 to 1130±145 jLM) compared to peripheral insulin infusion (714±100 to 866±142 ,uM). Net hepatic uptake of NEFA (Table IV) was also significantly increased (P < 0.001) during head (3.2±0.8 to 9.5±2.1 ,imol/kg per min) compared with peripheral infusion (2.3±0.5 to 3.6±0.9 umol/kg per min). Hepatic fractional extraction of NEFA remained at basal levels during peripheral insulin infusion (15±3%) but increased significantly during head insulin infusion (18±3 to 26±4%, P < 0.01). Blood acetoacetate and 3-hydroxybutyrate levels remained at basal levels during both insulin infusion protocols (Table  III) . Net Peripheral infusion 6020±300 5860±290 5880±300 5780±280 6438±345 4475±525 4030±218 3580±300 3320±300 3350±210 3320±220 3360±220
Head infusion 6460±300 6350±300 6250±300 6300±310 5880±610 4190±380 4060±540 3890±380 3830±400 3890±450 3870±500 3850±400
1.9±0.6 /Amol/kg per min, 3-hydroxybutyrate 1.0±0.4 to insulin infusion (158±9 to 147±7 vs. 156±6 to 138±8 mmHg, 2.7±1.0 pumol/kg per min, both P < 0.01).
respectively). Diastolic blood pressure was maintained at conCardiovascular parameters. Heart rate ( Fig. 5) sponse as glucose utilization was indistinguishable in the two protocols. Similarly, as peripheral insulin levels were identical, a potentially equivalent systemic vasodilatory stimulus would have been present in each protocol. In fact, mean arterial and diastolic blood pressure were lower during peripheral insulin than head insulin infusion ruling out a greater hypotensive signal being the cause of the augmented neuroendocrine response.
The present results clearly demonstrate that during hypoglycemia insulin can regulate the response of hormones and neurotransmitters released from peripheral tissues. Our results, on the other hand, do not provide any direct evidence that increased head levels of insulin can amplify release of pituitary hormones during hypoglycemia. However, as plasma cortisol levels were amplified during head insulin infusion, this would suggest that ACTH levels were also amplified during these experiments. This appears a reasonable speculation as (a) we are not aware of any other normal physiologic mechanism for cortisol secretion other than by pituitary derived ACTH, and (b) it is highly unlikely that under conditions of equivalent systemic hypoglycemia and insulinemia that adrenal gland sensitivity to ACTH could have been amplified or cortisol clearance could have been reduced during head compared with peripheral insulin infusion. Interestingly, we have data in man which supports the fact that insulin can regulate the release of pituitary hormones during hypoglycemia. In our previous studies growth hormone levels were amplified during hypoglycemia induced in the presence of high compared to lower levels of insulin ( 16, 41a the exception of the growth hormone response, qualitatively similar to man. The effects of insulin on the autonomic nervous system under hypoglycemic conditions have also been demonstrated to be similar in the two species (15) (16) . Thus the present finding may explain observations made in man concerning possible effects of insulin on the central nervous system. Kerr et al. (42) have reported increased cerebral blood flow during hyperinsulinemic euglycemia in normal man and Luzi et al. (43) have described an absence of the usual endogenous insulin suppression during hyperinsulinemic euglycemic clamps in denervated pancreatic transplanted IDDM subjects.
The increased metabolic and cardiovascular responses observed during the last 2 h of head insulin infusion are probably explained by amplified autonomic sympathoadrenal activity. Despite equivalent hepatic insulin and glucagon levels, the increased catecholamine levels (via circulation or neural input) was associated with a virtual doubling of hepatic glucose production during head insulin infusion. The increased HGP rate measured by tracer methodology was confirmed by direct net hepatic A-V difference data. The rates of glucose utilization (4.3±0.3 vs. 4.6±0.5 mg/kg per min) and clearance rates (7.6±0.6 vs. 7.8±0.7 ml/kg per min) were similar during both insulin infusion protocols despite the greatly increased catecholamine levels during head insulin infusion. The finding that the excess catecholamines did not further reduce glucose utilization during head infusion may be explained by the fact that only moderate increments in epinephrine and norepinephrine are required to maximally suppress insulin stimulated glucose clearance. Stevenson et al. (44) have demonstrated, in the dog, that the dose related effects of epinephrine to reduce glucose clearance reach a maximum at circulating levels of -440±70 pg/ml (well below levels of 792±198 pg/ml observed in the peripheral insulin studies). Furthermore previous in vitro studies (45) have demonstrated that epinephrine's effects on reducing glucose clearance in skeletal muscle plateau at concentrations of 10--10-8 M. These levels are very similar to the epinephrine levels reported by Stevenson et al. (44) in vivo. Thus, it appears clear that levels of epinephrine within the lower physiologic range exert a maximal effect on restraining glucose clearance. The mechanisms involved in epinephrine's action to suppress glucose clearance are not fully understood. However, recent work (46) has demonstrated that epinephrine may inhibit glucose clearance, in part, due to an increase in glucose-6-phosphate which in turn inhibits hexokinase.
Interestingly, there were differences in the source of glucose released by the liver during the head and peripheral insulin infusions. During the last hour of the present experiments, the initial glycogenolytic burst in response to hypoglycemia had waned and gluconeogenesis represented the process by which the elevated hepatic glucose production was sustained. In the head infusion group the minimal and maximal estimates of gluconeogenesis were 2.5 and 4.3 mg/kg per min, respectively. During the last hour of peripheral insulin infusion studies these estimates were 0.8 and 1.8 mg/kg per min. Thus gluconeogenesis was quantitatively more important during the head insulin infusions. As glucagon levels were similar during the last 2 h of both protocols this indicates that either the increased catecholamines and/or cortisol were responsible for the increased gluconeogenic rate when insulin was given into the head. Re (9, 53, 54) . The exact site of insulin sensing by the CNS is not known. However, as the responses of the autonomic nervous system and the hypothalamo-pituitary-adrenal response (cortisol) were amplified, it appears that the hypothalamus was either directly stimulated by insulin or that it was secondarily stimulated by other areas of the brain with pathways projecting into it. The cellular mechanisms responsible for insulin's metabolic effects on the brain are not fully ellucidated (54) . Recent work has demonstrated that insulin may directly increase noradrenergic turnover within the brain by inhibiting norepinephrine uptake in the synaptic cleft (55) . However, data concerning insulin's action on brain glucose and glycogen metabolism are in conflict, with reports which show either no effect or increased (15, 19, 20, 37) . These data coupled with microneurographic studies demonstrating increased sympathetic nerve activity during hyperinsulinemic euglycemia have provided a consensus that insulin can activate the sympathetic nervous system during euglycemic conditions. The situation during hyperinsulinemic hypoglycemic conditions has not been resolved. Although several studies (15, 16, 17) have reported amplification of the sympathetic nervous system by insulin during hypoglycemia, others have not (59, 60) . In fact one study has reported a suppression of epinephrine by insulin during hypoglycemic conditions (61) . There have been many differences in the design of the studies evaluating the effects of insulin per se during hypoglycemia. These have included (a) differing depth of hypoglycemia, (b) differing insulin levels, (c) differing duration of hypoglycemia, (d) prior hypoglycemic or hyperinsulinemic euglycemic periods, and (e) statistical power. It is, therefore, likely that the greatly varying experimental designs, in the above studies, has been the cause of much of the inconsistent data. The present results clearly answer two questions. First, they definitively support the finding that raised insulinemia in the brain can dramatically amplify the autonomic nervous system's counterregulatory response to hypoglycemia. Second, they demonstrate that increased physiologic insulinemia is sensed by the brain and as a result a large systemic increase in hormone secretion occurs and fuel mobilization is triggered.
In summary, these studies demonstrate that in the conscious normal dog, the brain is an insulin responsive organ. This finding is relevant since under hypoglycemic conditions the brain sensed a physiologic increase in blood borne insulin and as a result amplified the autonomic nervous system's counterregulatory response. This raises the possibility that small changes in the insulin level, such as occur over the course of a normal day, may result in discernable and meaningful alterations in autonomic function. To conclude, we suggest that the brain should be added to the list of mammalian tissues that are known to be sensitive to the direct effects of insulin.
